TrialInvestigational new drugs2008

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Andrew H Ko et al.PubMed ↗Publisher ↗

No numbers read from the abstract.